Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Gilead Sciences Inc (NASDAQ:GILD)

Thursday’s Trading Day
87.36 -0.44 / -0.50%
As of Feb 11
Day’s Change
Friday’s Pre-Market   Switch to standard view »
87.96 +0.60 / +0.69%
 
Volume: 200.00
Roche to Stop Study on Lung Cancer Drug Alecensa Early
Feb 11 / Zacks.com
Play Strong Defense With 3 Big Biotechs
Feb 07 / TheStreet.com
Genomic Health Q4 Loss Wider than Expected, Revenues Up
Feb 11 / Zacks.com
Is Gilead Sciences Finally Nearing a Bottom?
Feb 07 / MotleyFool.com
GW Pharmaceuticals Up on Narrower-than-Expected Q1 Loss
Feb 11 / Zacks.com
Rx for Success: Play Defense With Big Biotech
Feb 07 / TheStreet.com
Friday Sector Leaders: Healthcare, Utilities
Feb 11 / TheOnlineInvestor.com
Grading Gilead Sciences' Performance in 2015
Feb 06 / MotleyFool.com
Gilead Sciences Popular Amongst Latest 13F Filers
Feb 11 / HoldingsChannel.com
1 Company Gilead Sciences Should Consider Buying Right Now
Feb 06 / MotleyFool.com
Gilead Sciences Becomes Oversold (GILD)
Feb 11 / DividendChannel.com
Gilead Sciences 2016 Guidance: Sandbagging Wall Street Again?
Feb 05 / MotleyFool.com
Buying Biotechs
Feb 11 / TheStreet.com
Gilead's Glory Days Are Over -- Here's Why You Should Dump the Stock
Feb 05 / TheStreet.com
Pfizer's Biosimilar of Remicade Recommended for Approval
Feb 10 / Zacks.com
Gilead Sciences (GILD) Stock Gets ‘Outperform’ Rating at Leerink
Feb 05 / TheStreet.com
Nasdaq Perilously Close to Bear Market: 5 Growth Stocks on Sale
Feb 10 / Zacks.com
5 Stocks We're Buying Again
Feb 05 / MotleyFool.com
CTI BioPharma's Myelofibrosis Drug on Full Clinical Hold
Feb 10 / Zacks.com
4 Can't-Miss Numbers From GlaxoSmithKline's Fourth-Quarter Results
Feb 04 / MotleyFool.com
Gilead Sciences Inc.'s Outlook For 2016: What Investors Need to Know
Feb 10 / MotleyFool.com
Why Achillion Pharmaceuticals Shares Crashed 37% in January
Feb 04 / MotleyFool.com
Gilead (GILD) Stock Gains, Barclays Sees Upside Potential for Hep-C Drugs
Feb 10 / TheStreet.com
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Intrexon and NewLink
Feb 04 / Zacks.com
Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma
Feb 10 / Zacks.com
Why Did Biotech Fall Off a Cliff in January?
Feb 04 / MotleyFool.com
Stock Market News for February 10, 2016
Feb 10 / Zacks.com
Gilead's Stock is on Sale: Should You Buy?
Feb 03 / Zacks.com
What to Expect from Gilead Sciences, Inc.'s New CEO
Feb 10 / MotleyFool.com
Forget Gilead Sciences: These Stocks Doubled Last Year
Feb 03 / MotleyFool.com
3 Biotech Stocks to Buy in a Market Crash
Feb 09 / MotleyFool.com
Instant Analysis: Gilead Sciences Raises Its Dividend 10%
Feb 03 / MotleyFool.com
Biotech ETFs Slide as Stocks Report Mixed Q4 Results
Feb 09 / Zacks.com
Myriad Genetics Tops Q2 Earnings; myRisk Conversion Over
Feb 03 / Zacks.com
The Agony of High Returns
Feb 09 / MotleyFool.com
Qiagen Q4 Earnings Miss, Molecular Diagnostics Disappoints
Feb 03 / Zacks.com
Why the Nasdaq is on the verge of a bear market
Feb 09 / CNNMoney.com
International Growth Propels Gilead Sciences Inc.'s Solid Q4 Results
Feb 03 / MotleyFool.com
Curing Hepatitis C: How Gilead Sciences Plans to Beat Merck
Feb 09 / MotleyFool.com
Alexion Misses on Earnings and Revenues in Q4, Gives View
Feb 03 / Zacks.com
Bristol-Myers' Daklinza-Sovaldi Label Expanded by the FDA
Feb 08 / Zacks.com
Merck Tops on Q4 Earnings, Revenue Outlook Falls Short
Feb 03 / Zacks.com
Will Gilead Sciences, Inc. Continue to Dominate HIV Treatment?
Feb 08 / MotleyFool.com
The Zacks Analyst Blog Highlights: Yahoo, Chipotle, Gilead Sciences and Match Group
Feb 03 / Zacks.com
Morning Buzz: Yelp (YELP), Celgene (CELG), Gilead Sciences (GILD), Apple (AAPL), GoPr...
Feb 08 / Investing Channel
The Zacks Analyst Blog Highlights: Darden Restaurants, KLA-Tencor, Motorola Solutions...
Feb 03 / Zacks.com
3 Health Care Stocks On The Rise
Feb 08 / TheStreet.com
The Zacks Analyst Blog Highlights: Gilead Sciences, Mylan, United Therapeutics and IN...
Feb 03 / Zacks.com
Why Gilead Sciences (GILD) Stock May Advance Today
Feb 08 / TheStreet.com
Gilead (GILD) Beats Q4 Earnings Estimates, Gives 2016 View
Feb 03 / Zacks.com